Search Result

Results for "

LDHA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminotransferases (Transaminases) (1) Apoptosis (9) Histone Methyltransferase (1) Lactate Dehydrogenase (23) PDK-1 (2) PROTACs (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (24) Metabolic Disease (2)
Click Chemistry:	PROTAC Synthesis (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139319

LDHA-IN-3 2 Publications Verification	Lactate Dehydrogenase	Cancer
LDHA-IN-3 (compound 2), as a selenobenzene compound, is a potent, noncompetitive lactate dehydrogenase (LDHA) inhibitor (IC₅₀=145.2 nM). LDHA-IN-3 can be used for the research of cancer .

HY-18968

AZ-33 1 Publications Verification LDHA-IN-4	Lactate Dehydrogenase	Cancer
AZ-33 (LDHA-IN-4) (compound 33) is a selective lactate dehydrogenase A (LDHA) inhibitor with an IC₅₀ of 0.5 μM and a K_d of 0.093 μM .

HY-146977

LDHA/PDKs-IN-1	PDK-1	Cancer
LDHA/PDKs-IN-1 (compound 20e) is a potent and dual inhibitor of PDKs and LDHA with IC₅₀s of 0.8 and 0.15 μM, respectively. LDHA/PDKs-IN-1 reduces A549 cell proliferation with an EC₅₀ of 13.2 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-1 has the potential for the research of cancer diseases .

HY-146978

LDHA/PDKs-IN-2	PDK-1	Cancer
LDHA/PDKs-IN-2 (compound 20k) is a potent and dual inhibitor of PDKs and LDHA with IC₅₀s of 1.6 and 0.7 μM, respectively. LDHA/PDKs-IN-2 reduces A549 cell proliferation with an EC₅₀ of 15.7 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-2 has the potential for the research of cancer diseases .

HY-162627

LDHA-IN-6	Lactate Dehydrogenase	Cancer
LDHA-IN-6 (compound 6) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA), with the IC₅₀ of 46 nM. LDHA-IN-6 has antitumor activity .

HY-169060

LDHA-IN-8	Lactate Dehydrogenase	Cancer
LDHA-IN-8 (Compound 6) is a lactate dehydrogenase (LDHA) inhibitor. LDHA-IN-8 inhibits *LDHA* catalysis of pyruvate in a dose-dependent manner (EC₅₀ value of 14.54 μM), reduces intracellular lactate levels, and increases intracellular reactive oxygen species (ROS) levels, thereby inhibiting the proliferation of pancreatic cancer cells and lung cancer cells. LDHA-IN-8 holds promise for research in the field of LDHA-related antitumor therapies .

HY-115875

LDHA-IN-5	Lactate Dehydrogenase	Metabolic Disease
LDHA-IN-5 is a novel, potent, dual *GO/LDHA* inhibitor for primary hyperoxaluria.

HY-168733

LDHA-IN-9	Lactate Dehydrogenase Apoptosis	Cancer
LDHA-IN-9 (Compound 1g) is an inhibitor for *LDH-A* with an IC₅₀ of 25 nM. LDHA-IN-9 inhibits the proliferation of DLD-1 cell (GI₅₀ of 27 μM) through apoptosis induction. LDHA-IN-9 exhibits antitumor activity in mouse model without significant toxicity (25 mg/kg) .

HY-162629

LDHA-IN-7	Lactate Dehydrogenase	Cancer
LDHA-IN-7 (compound 21) is an oral bioactive inhibitor of lactate dehydrogenase-A (LDHA) and LDHB, with the IC₅₀s of 72 nM and 1.2 Μm, respectively .

HY-RS22935

Ldha Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ldha Rat Pre-designed siRNA Set A contains three designed siRNAs for Ldha gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ldha Rat Pre-designed siRNA Set A Ldha Rat Pre-designed siRNA Set A

HY-RS07571

LDHA Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LDHA Human Pre-designed siRNA Set A contains three designed siRNAs for LDHA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LDHA Human Pre-designed siRNA Set A LDHA Human Pre-designed siRNA Set A

HY-RS16503

Ldha Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ldha Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ldha gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ldha Mouse Pre-designed siRNA Set A Ldha Mouse Pre-designed siRNA Set A

HY-16214

FX-11 20+ Cited Publications LDHA Inhibitor FX11	Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS)	Cancer
FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a K_i of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .

HY-100742

GNE-140 racemate 5+ Cited Publications	Lactate Dehydrogenase	Cancer
GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor .

HY-169061

WQQ-345	Histone Methyltransferase Aminotransferases (Transaminases) Lactate Dehydrogenase	Cancer
WQQ-345 is a BCAT1 inhibitor with an IC₅₀ value of 10.8 mM. WQQ-345 can lead to a decrease in α-KG levels, an upregulation of H3K27me3 expression, a reduction in the expression of glycolytic enzymes (PFKP and *LDHA*), and impaired glycolytic activity in 67R cells. WQQ-345 shows tumor-suppressing activity in a 67R subcutaneous xenograft model .

HY-152261

MS6105	PROTACs	Cancer
MS6105 is an LDH protein hydrolysis-targeted chimera (PROTAC) that effectively degrades LDHA and LDHB in a time- and ubiquitin-proteasome system-dependent manner and has anticancer activity . MS6105 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100742A

(R)-GNE-140 10+ Cited Publications	Lactate Dehydrogenase	Cancer
(R)-GNE-140 is a potent lactate dehydrogenase A (LDHA) inhibitor, with IC₅₀s of 3 nM and 5 nM for LDHA and LDHB, respectively; (R)-GNE-140 is 18-fold more potent than S enantiomer.

HY-100742B

(S)-GNE-140	Lactate Dehydrogenase	Cancer
(S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).

HY-100681

GSK2837808A 30+ Cited Publications	Lactate Dehydrogenase	Cancer
GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC₅₀s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.

HY-111108

LDH-IN-1 2 Publications Verification	Lactate Dehydrogenase	Cancer
LDH-IN-1 is a novel pyrazole-based inhibitor of human lactate dehydrogenase (LDH) with IC₅₀s of 32 and 27 nM for LDHA and LDHB, respectively.

HY-147361

LDCA	Apoptosis Lactate Dehydrogenase	Cancer
LDCA is a dual-hit metabolic modulator and inhibits *LDH-A* enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression .

HY-W013032

Oxamic acid Maximum Cited Publications 38 Publications Verification Oxamidic acid	Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-W013032A

Oxamic acid sodium Maximum Cited Publications 38 Publications Verification Sodium oxamate	Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid (oxamate) sodium salt is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid sodium salt shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-156683

CHK-336	Lactate Dehydrogenase	Metabolic Disease
CHK-336 (Example 1) is an orally active *LDHA* inhibitor (IC₅₀<1 nM) that inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria .

HY-W040118

Galloflavin 5+ Cited Publications	Lactate Dehydrogenase	Cancer
Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated K_is for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .

HY-124309

NHI-2	Lactate Dehydrogenase Apoptosis	Cancer
NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC₅₀ of 14.7 µM. NHI-2 shows selective for *LDHA* over LDHB (IC₅₀ = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .

HY-W013032R

Oxamic acid (Standard) Oxamidic acid (Standard)	Reference Standards Lactate Dehydrogenase Apoptosis	Cancer
Oxamic acid (Standard) is the analytical standard of Oxamic acid. This product is intended for research and analytical applications. Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].

HY-175230

ZG-2492	Lactate Dehydrogenase Apoptosis	Cancer
ZG-2492 is an orally active *LDHA* inhibitor with an IC₅₀ of 156 nM. ZG-2492 can reduce lactate production and induce cell cycle arrest and apoptosis in pancreatic cancer cells . ZG-2492 has antitumor activity and can be used in the research of tumors such as pancreatic cancer .

HY-176798

NCI-006	Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis	Cancer
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC₅₀ = 0.06 μM; LDHB IC₅₀ = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W013032

Oxamic acid 35+ Cited Publications Oxamidic acid	Microorganisms Source classification	Lactate Dehydrogenase Apoptosis
Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis .

HY-W013032R

Oxamic acid (Standard) Oxamidic acid (Standard)	Microorganisms Source classification	Reference Standards Lactate Dehydrogenase Apoptosis
Oxamic acid (Standard) is the analytical standard of Oxamic acid. This product is intended for research and analytical applications. Oxamic acid is a lactate dehydrogenase-A (LDH-A) inhibitor. Oxamic acid shows anti-tumor activity, and anti-proliferative activity against cancer cells, and can induce apoptosis[1][2][3].

Species:	Human (1) Mouse (2) Rat (1)
Tag:	His (4)
Source:	HEK293 (1) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P73271

	LDHA Protein, Rat (His) L-lactate dehydrogenase A chain; LDH-A; LDH-M; LDHA; Ldh-1	Rat	E. coli
	The LDHA protein facilitates the simultaneous and stereospecific interconversion of pyruvate and lactate, accompanied by the concomitant exchange of NADH and NAD(+).LDHA Protein, Rat (His) is the recombinant rat-derived LDHA protein, expressed by E.coli , with N-His labeled tag.

HY-P70259

	LDHA Protein, Mouse (HEK293, His) rMuL-lactate dehydrogenase, His; LDHA; Ldh1; L-lactate dehydrogenase	Mouse	HEK293
	LDHA protein catalyzes the simultaneous and stereospecific interconversion of pyruvate and lactate, accompanied by the reciprocal interconversion of NADH and NAD(+).LDHA Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDHA protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70225

	LDHA Protein, Human (His) rHuL-lactate dehydrogenase A chain/LDH-A, His; L-Lactate Dehydrogenase A Chain; LDH-A; Cell Proliferation-Inducing Gene 19 Protein; LDH Muscle Subunit; LDH-M; Renal Carcinoma Antigen NY-REN-59; LDHA	Human	E. coli
	LDHA protein catalyzes the stereospecific interconversion of pyruvate and lactate, concomitantly exchanging NADH and NAD(+). LDHA Protein, Human (His) is the recombinant human-derived LDHA protein, expressed by E. coli , with N-6*His labeled tag.

HY-P73270

	LDHA Protein, Mouse (His) L-lactate dehydrogenase A chain; LDH-A; LDH-M; LDHA; Ldh-1	Mouse	E. coli
	LDHA protein catalyzes the simultaneous and stereospecific interconversion of pyruvate and lactate, accompanied by the reciprocal interconversion of NADH and NAD(+).LDHA Protein, Mouse (His) is the recombinant mouse-derived LDHA protein, expressed by E.coli , with N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80738

	Lactate Dehydrogenase A Antibody (YA317) LDHA; LDH-M; LDH1; PIG19; GSD11; TRG5; Proliferation inducing gene 19	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Rat
	Lactate Dehydrogenase A Antibody (YA317) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lactate Dehydrogenase A.

HY-P86602

	Lactate Dehydrogenase Antibody (YA6294) LDHA; PIG19; LDHB; LDHC; LDH3; LDHX; L-lactate dehydrogenase A chain; LDH-A; Cell proliferation-inducing gene 19 protein; LDH muscle subunit; LDH-M; Renal carcinoma antigen NY-REN-59; L-lactate dehydrogenase B chain; LDH-B; LDH heart subunit; LDH-H; Renal carcinoma antigen NY-REN-46; L-lactate dehydrogenase C chain; LDH-C; Cancer/testis antigen 32; CT32; LDH testis subunit; LDH-X;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Lactate Dehydrogenase Antibody (YA6294) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lactate Dehydrogenase.